biotech · Neuroblastoma · Hyperinflammation, Sepsis · AXIM
AXIM Biotechnologies
AXIM BIOTECHNOLOGIES, INC.
AXIM Biotechnologies is a biotech organization headquartered in New York, USA. It trades on NYSE under ticker AXIM. Primary therapeutic focus areas include Neuroblastoma, Hyperinflammation, Sepsis, craniopharyngioma, Del
18 East 50th Street, 5 Floor, New York, NY 10022, US HQ
2011 Founded
7 Employees
Public company Type
AXIM · NYSE Ticker
Company details
- Status
- Public
- HQ
- 18 East 50th Street, 5 Floor, New York, NY 10022, US
- Founded
- 2011
- Employees
- 7
- Programs
- 20
- Drugs
- 52
- Patents
- 138
ONC206 Powder
Phase 1 · small molecule · Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors
ONC206 Powder for Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors is a Phase 1 program (small_molecule) at AXIM BIOTECHNOLOGIES, INC. with 1 ClinicalTrials.gov record(s).
Internal code PNOC023
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- AXIM BIOTECHNOLOGIES, INC.
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors
- Status
- active
- Trials
- 1